title: Addressing the controversy: do bisphosphonates directly affect primary tumors?
abstract: The recent article by Junankar and colleagues focuses on demonstrating the uptake of bisphosphonates (BP) into the primary tumor in both animal models and human samples. Interestingly, the authors were able to establish tumor-associated macrophages as the cell type that takes up the BPs. These studies are an important advancement for understanding the potential benefits of using BPs as adjuvant therapy in patients with cancer.
authors.affiliation: Department of Veterans Affairs, Tennessee Valley Healthcare System, Nashville, Tennessee. Vanderbilt Center for Bone Biology, Department of Medicine, Division of Clinical Pharmacology, Nashville, Tennessee. Department of Cancer Biology, Vanderbilt University, Nashville, Tennessee. Julie.sterling@vanderbilt.edu.
authors.forename: Julie A
authors.initials: JA
authors.lastname: Sterling
mesh_terms: D000818:Animals; D050071:Bone Density Conservation Agents / Q000378:metabolism*; D004164:Diphosphonates / Q000378:metabolism*; D005260:Female; D006801:Humans; D008264:Macrophages / Q000378:metabolism*; D009369:Neoplasms / Q000175:diagnosis*; D015899:Tomography, Emission-Computed, Single-Photon; D014057:Tomography, X-Ray Computed
chemical_list: D050071:Bone Density Conservation Agents; D004164:Diphosphonates